Assoc. Prof. Urh Grošelj, MD, MA, graduated (2007) and obtained his PhD (2012) from the Faculty of Medicine, University of Ljubljana, Slovenia, and earned a Master’s degree (2008, summa cum laude) from the University of Leuven, Belgium. During his undergraduate studies, he served as Editor-in-Chief of the journal Medicinski razgledi. Since 2013, he has been a member of the Slovenian National Medical Ethics Committee. Since 2014, he has been working as a specialist pediatrician at the Department of Pediatrics, University Medical Centre Ljubljana. Since 2022, he has been an Associate Professor of Pediatrics and Assistant Professor of Medical Ethics, and a member of the Department of Pediatrics and the Department of Medical Ethics at the Faculty of Medicine, University of Ljubljana. In the academic year 2021/2022, he was a Fulbright Scholar and a visiting lecturer and researcher at the Stanford University School of Medicine, USA.

He leads the Slovenian national universal screening program for familial hypercholesterolemia. He coordinates the national newborn screening program (including its expansions in 2018 and 2024–2025), as well as the Slovenian National Registry for Rare Non-Malignant Diseases, within the Centre for Rare Diseases at the Department of Pediatrics, University Medical Centre Ljubljana. He is the national co-lead of the European Atherosclerosis Society (EAS) Lipid Clinics Network and the national lead of the international Familial Hypercholesterolemia Studies Collaboration (EAS FHSC). Since 2024, he has served as Vice-President of the Slovenian Heart Foundation. Since 2025, he has been Chair of the Genomics Committee of the International Society for Neonatal Screening (ISNS), and a founding member of the Pediatric Lipidology Working Group of the European Atherosclerosis Society (EAS PLWG). He is also a member of the Scientific Advisory Board of FH Europe and a member of the Newborn Screening Working Group of EURORDIS. He is also an “Emerging Leader” of the World Heart Federation (WHF).

He is an active researcher in the fields of metabolic disorders, rare diseases, dyslipidemias, and medical ethics. He has (co-)authored more than 130 articles indexed in PubMed and has an h-index of 30.